Neukio Biotherapeutics has completed a Series A-1 financing, to accelerate the discovery and development of next-generation cell therapy products

SHANGHAI, September 2, 2022 /PRNewswire/ — Neukio Biotherapeutics, a company committed to the development of novel cell therapy products, announces that it has closed $50 million in a Series A-1 funding round. The investment round was led by CD Capital, with the participation of Alwin Capital and Surplus Capital as new investors. Existing shareholders Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital continued to support the company with additional funding. G&G Capital served as exclusive financial advisor. Funds raised will play an important role in accelerating preclinical and clinical validation of ready-to-use induced pluripotent stem cell (iPSC)-derived CAR-NK cell therapy products, and supporting recruitment and team expansion.

Neukio, founded at Simbay Park in the Shanghai Pilot Free Trade Zone (China) in June 2021, is an innovative biotherapeutics company focused on the development and commercialization of next-generation immune cell therapy. Leveraging its significant experience in R&D, CMC and commercialization of autologous CAR-T cell therapy, Neukio’s management team established a pipeline development strategy based on iPSC-CAR-NK, aiming to launch ready-to-use allogeneic cell therapy products that can be produced on a large scale for the treatment of solid tumors. The company is focused on both in-house R&D innovation and global collaboration with leading partners, to deliver valuable clinical solutions to cancer patients worldwide. Since its inception just over a year ago, the company has made remarkable progress in recruiting talent, building facilities, advancing the R&D pipeline and establishing a quality management, exceeding all expectations.

dr. Richard Liquun Wangfounder, chairman and CEO of Neukio and former founding CEO of Fosun Kite Biotechnology Co., Ltd., successfully brought China’s first CAR-T cell therapy product Yescarca (Axicabtagene Ciloleucel) to market in less than four years, has laid the foundation for the cell therapy industry by China. To address the challenges of manufacturing, clinical application, and patient access to autologous cell therapy, Dr. Wang and the Neukio team are aiming high to create novel cell therapies to benefit cancer patients. by exploiting the clonality and unlimited replication capacity of iPSCs in conjunction with cutting-edge gene editing technologies.

Dr. Wang commented, “In as little as 10 months since operating our new labs, not only have we achieved several signaling pathway modifications and CAR designs suitable for solid tumors, but we have also made significant progress. in the development of innovative products. NK’s process of differentiation and expansion In today’s challenging capital market environment, we are honored to have received recognition from CD Capital, Alwin Capita, Surplus Capital and previous investors Sherpa Healthcare Partners, Lilly Asia Ventures and IDG Capital for our R&D strategy, development capabilities and project progress. I am very grateful to all of the investors and to G&G Capital and Silkroad Law Firm for their support in this funding round, and we will reward them by advancing rapidly in the preclinical and clinical validation of our R&D platform The field of cell therapy is progressing quickly with a promising future and huge market potential, and I PSC-CAR-NK therapy has the potential to become one of the brightest stars in next-generation cell therapy.”

“The transition from small molecules and traditional antibodies to the era of cell therapy is a great leap forward in human drug design and manufacturing capabilities,” said CD Capital, lead investor in this round of financing. “With the commercialization of autologous CAR-T cell products, more and more opportunities for improvement have emerged and must be urgently seized. In the field of cell therapy, CD Capital continues to focus on innovations and breakthroughs in allogeneic products to conquer solid tumors.Neukio has been deeply committed to iPSC-CAR-NK cell therapy.In a short time after its establishment, Neukio has established world-leading technology platforms effectively, both in scientific innovation and process development, demonstrating its strong execution ability and efficiency.We hope that the company under the leadership of Dr. Wang will adhere to pragmatism, efficiency and innovation, leading the advancement of the industry and bringing a new generation of allogeneic cell therapy products to clinical application as soon as possible for the benefit of patients. “

About CD Capital

CD Capital is an investment company specializing in innovative medical technologies and cutting-edge biotechnologies. Managed by a team of professionals with high-level training in the medical industry, it manages several funds in USD and RMB. By adhering to the investment philosophy of “Focus, Excellence and Reputation” and leveraging its abundant industry resources and years of extensive research and culture in the medical field, CD Capital is able to gain insight first-hand of the latest international trends. scientific and technological trends and seize the investment opportunities brought by technological innovation. CD Capital is committed to identifying top companies with industry leadership potential, builds an industry ecosystem and grows with entrepreneurs through the interconnected, win-win investment methodology and post-investment empowerment system precise and pragmatic, and creates sustainable and excellent returns for investors.

About Alwin Capital

Focusing on the frontier areas of life sciences, Alwin Capital conducts deep research, unifies knowledge and practice, walks in nonconsensual areas, and invests objectively and honestly in real opportunities for medical transformation. With a core team of industry and capital market veterans, Alwin Capital believes in the power of research, is committed to long-term investing, steadily builds corporate ecology and s strives to achieve systematic excess returns for investors.

About Excess Capital

Surplus Capital is committed to discovering and supporting medical companies that promote the health of all humanity. It focuses on subdivision areas such as innovative medicines and innovative medical devices, and adopts diversified investment strategies to pay attention to all stages of business development, including start-up, growth and maturity. Surplus Capital also cultivates sources of seed-stage projects and invests in and helps incubate high-quality seed-stage projects to help companies create value.

About Lilly Asia Ventures

Founded in 2008, Lilly Asia Ventures (LAV) is a leading venture capital fund company focused on investing in the life sciences and healthcare sectors with offices in Shanghai, hong kong, and Silicon Valley. LAV is committed to being a trusted partner for exceptional entrepreneurs seeking smart capital, and looks forward to working with top entrepreneurs to build great companies developing breakthrough products that treat disease and improve human health.

About Sherpa Healthcare Partners

Sherpa Healthcare Partners (Sherpa) is a professional fund company specializing in early stage healthcare and medical investments. It adheres to the investment concept of building industry ecology, builds portfolios for rigid unmet medical needs based on a thorough understanding of the treatment of critical illnesses, and plans the layout along the depth industry and upstream and downstream. By actively sharing the operational experience and forward-looking outlook of the whole industry chain with invested companies, Sherpa’s team actively promotes internal and external synergy, helping companies achieve rapid growth both in terms of commercial performance and value and take a leading position in their market. segments. It has invested in leading companies in sub-divisions such as medical services, medicine, genetic technology and medical devices, forming a full range of resource advantages in project sources, value services added post-investment, exits, etc. From 2011 to 2022, after 4 years of funds and more than 100 medical projects, Sherpa has grown hand in hand with many exceptional entrepreneurs.

About IDG Capital

IDG Capital pioneered venture capital in China in 1993. For years, IDG Capital has consistently pursued long-term value investing and maintained close long-term relationships with various investment partners around the world. IDG capital has accumulated extensive investment experience in venture capital, private equity and industrial development. It focuses on the following areas including consumer goods, service chains, internet and wireless applications, new media, education, healthcare, new energy, advanced manufacturing, etc. The investment covers companies at all stages of development: start-up, growth, mature and pre-IPO, with an investment size ranging from millions to tens of millions of US dollars.

For more information and updates on Neukio Therapeutics, please visit the Company’s website at www.neukio.com.

SOURCENeukio Biotherapeutics

Comments are closed.